UBS/CALL/BB BIOTECH N/50.003/0.0333/20.12.24 Share Price

Warrant

NBIO4U

CH1276034886

Market Closed - Swiss Exchange 08:45:00 05/06/2024 pm IST
0.02 CHF 0.00% Intraday chart for UBS/CALL/BB BIOTECH N/50.003/0.0333/20.12.24
6 months-33.33%
Current year-50.00%

Static data

Product typeWarrants
Buy / SellCALL
Underlying BB BIOTECH AG
Issuer UBS
NBIO4U
ISINCH1276034886
Date issued 19/06/2023
Strike 50 CHF
Maturity 20/12/2024 (188 Days)
Parity 30 : 1
Emission price 0.09 CHF
Emission volume N/A
Settlement physique
Currency CHF

Technical Indicators

Highest since issue 0.12 CHF
Lowest since issue 0.02 CHF
Delta0.13x
Omega 11.64
Premium27.25x
Gearing88.11x
Moneyness 0.7930
Difference Strike 10.35 CHF
Difference Strike %+20.70%
Spread 0.01 CHF
Spread %50.00%
Theoretical value 0.0150
Implied Volatility 25.71 %
Total Loss Probability 90.36 %
Intrinsic value 0.000000
Present value 0.0150
Break even 50.45 CHF
Theta-0x
Vega0x
Rho0x

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
39.65 CHF
Average target price
47.7 CHF
Spread / Average Target
+20.30%
Consensus
  1. Stock Market
  2. Warrants
  3. NBIO4U Warrant